Martin Zamora, MD
Critical Care Medicine · Orlando, FLNPI 1801986583
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by CSL Behring at 34.1% of the total. Reporting peaked in 2019 at $19,753 and has fallen 81.8% since, to $3,593 in 2025. Among critical care medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $528.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$15K
- Kamada Ltd.$9K
- Merck$7K
- Grifols Shared Services North America, Inc.$6K
- Biotest AG$5K
- La Jolla Pharmaceutical Company$988
- plus $2K from 18 others
Across 8 payments — averaging $5172.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$41K
What the payments were for
- Consulting fees$15,76636%
- Speaking & faculty fees$21,21448%
- Travel & lodging$2,2945%
- Food & beverage$5,11712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 11 | $15,142 |
| Kamada Ltd. | 18 | $9,368 |
| Merck | 9 | $6,510 |
| Grifols Shared Services North America, Inc. | 6 | $5,978 |
| Biotest AG | 2 | $4,626 |
| La Jolla Pharmaceutical Company | 11 | $988 |
| AbbVie(2 entities) | 5 | $465 |
| Boehringer Ingelheim | 5 | $215 |
| Atricure, Inc. | 1 | $170 |
| AstraZeneca | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| GSK | 1 | $118 |
| Actelion Pharmaceuticals US, Inc. | 1 | $108 |
| Sanofi | 1 | $103 |
| Veloxis Pharmaceuticals, Inc. | 1 | $91 |
| United Therapeutics Corporation | 1 | $50 |
| Vapotherm Inc | 2 | $49 |
| Baxter Healthcare | 1 | $31 |
| Alcresta Therapeutics, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Fisher & Paykel Healthcare Inc | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $23 |
| Masimo Corporation | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,391 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CresembaIsavuconazonium Sulfate | 24 | $151,591 |
| PrevymisLetermovir | 16 | $107,885 |
| DificidFidaxomicin | 15 | $48,509 |
| Atovaquone | 44 | $26,685 |
| EliquisApixaban | 15 | $11,107 |
| Tacrolimus | 57 | $8,784 |
| Enoxaparin Sodium | 13 | $5,511 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $4,888 |
| Hydrocortisone | 80 | $4,550 |
| Valganciclovir Hcl | 28 | $4,545 |
| Mycophenolate Mofetil | 38 | $3,659 |
| Voriconazole | 12 | $2,111 |
| Acyclovir | 101 | $1,854 |
| Azithromycin | 90 | $1,727 |
| Montelukast Sodium | 45 | $681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckPrevymis, Dificid | $6,510 | $156,39431 claims |
| Astellas Pharma US IncCresemba | $25 | $151,59124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 critical care medicine providers in Florida.
Other critical care medicine in Orlando
- Louis GuzziOrlando$635K
- Omid ZadOrlando$325K
- Charles HunleyOrlando$116K
- Hammad BhattiOrlando$41K
- Dmitriy ZubkusOrlando$22K
- Amay ParikhOrlando$8K
- Sundeep GulianiOrlando$6K
- Fortune AlabiKissimmee$587K
- Debabrata BandyopadhyayTampa$398K
- Fred UmehKissimmee$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.